Structured across aging pathways, clinical stage and capital activity.
Disease focus, clinical stage, drug market analysis, biologic target, target validation, MOA, therapeutic indication.
Mapped across therapeutic focus, aging pathways, aging hallmarks and much more.
Clinical progress, funding, IP, partnerships and talent movement.
The platform continuously tracks:
All mapped to aging biology.
At the centre of DLT is a custom-built intelligence chatbot that queries the live dataset in real time.
This is not a general-purpose LLM.
It operates inside a structured longevity corpus and retrieves traceable company-level data. Instead of navigating dashboards, you ask, literally anything.
Find biotech companies working on specific aging mechanisms, therapeutic areas, or drug targets (e.g., "Which companies are targeting cellular senescence?")
Generate charts and breakdowns across the longevity space (e.g., "Show the distribution of assets by hallmark of aging")
Identify top-funded companies, funding status, and grant recipients (e.g., "Who are the top 10 most funded longevity biotechs?")
Pull together everything known about a specific company — its assets, team, patents, clinical trials, and more (e.g., "Tell me everything about BioAge"; "Build me a senolytics market intelligence report")
| Capability | DLT | CB Insights | Citeline | GlobalData |
|---|---|---|---|---|
|
Longevity-native dataset |
|
|
|
|
|
Hallmarks-of-aging mapping |
|
|
|
|
|
Structured aging-pathway analysis |
|
|
|
|
|
Repurposing signal detection |
|
Limited |
Limited |
Limited |
|
AI querying across structured longevity data |
|
|
|
|
|
AI querying across structured longevity data blended with external LLM enrichment |
|
|
|
|
